Mark Kirby

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri, Jeffrey A. Robl, David A. Betebenner et al. · Journal of Medicinal Chemistry · 2005 · 621 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Genetic Control of Obesity and Gut Microbiota Composition in Response to High-Fat, High-Sucrose Diet in Mice

Brian W. Parks, Elizabeth Nam, Elin Org et al. · Cell Metabolism · 2013 · 552 citations · Full text

Life Sciences, Genetics, Nutritional Sciences +16

Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation

William J. Metzler, Joseph Yanchunas, Carolyn A. Weigelt et al. · Protein Science · 2008 · 128 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

Two-photon-excitation fluorescence imaging of three-dimensional calcium-ion activity

David W. Piston, Mark Kirby, Heping Cheng et al. · Applied Optics · 1994 · 106 citations

Natural Sciences, Biophysics, Cell Biology +17

Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections

Aberra Fura, Ashish K. Khanna, Viral Vyas et al. · Drug Metabolism and Disposition · 2009 · 99 citations

Pharmacy, Pharmacokinetics, Pharmacology +14